Literature DB >> 10214558

A double-blind study of the sedative effects of the thalidomide enantiomers in humans.

P Höglund1, T Eriksson, S Björkman.   

Abstract

This study investigated the sedative effects of the enantiomers of thalidomide in humans. Since the enantiomers undergo chiral inversion in vivo this entailed application of suitable statistical methodology to distinguish the effects of each enantiomer in the presence of the other one. Six healthy male volunteers received single oral doses of (+)-(R)-thalidomide, (-)-(S)-thalidomide or racemic thalidomide in a double-blind study, and the results of this study were compared with those of a similar study where three subjects received (+)-(R)-thalidomide, (-)-(S)-thalidomide or placebo in a double-blind fashion. Blood samples for analysis of (+)-(R)-thalidomide and (-)-(S)-thalidomide were obtained. Prior to sampling it was noted whether the subject was awake or asleep, and his feelings of tiredness and heaviness were estimated using Borg scales. After blood sampling continuous reaction time was measured by a 10-min series of auditory signals. The concentration-effect relationships were analyzed by logistic regression techniques and Cox regression for the reaction time data. The (+)-(R)-thalidomide concentrations, but not the (-)-(S)-thalidomide concentrations, exhibited significant positive influences on all sedative effects studied (sleep, tiredness, and reaction times). In some of the analyses of reaction times the (-)-(S)-thalidomide concentrations had a significant effect in the opposite direction. The time course and intensity of sedative effect is thus influenced by which enantiomer is administered and by the kinetics of in vivo chiral inversion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10214558     DOI: 10.1023/a:1021008016719

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  26 in total

1.  Thalidomide back--under strict control.

Authors:  C Marwick
Journal:  JAMA       Date:  1997-10-08       Impact factor: 56.272

2.  Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers.

Authors:  T L Chen; G B Vogelsang; B G Petty; R B Brundrett; D A Noe; G W Santos; O M Colvin
Journal:  Drug Metab Dispos       Date:  1989 Jul-Aug       Impact factor: 3.922

Review 3.  Thalidomide and congeners as anti-inflammatory agents.

Authors:  H P Koch
Journal:  Prog Med Chem       Date:  1985

4.  Quantitative evaluation of chest pain.

Authors:  G Borg; A Holmgren; I Lindblad
Journal:  Acta Med Scand Suppl       Date:  1981

5.  Toxicity and teratogenicity of optical isomers of thalidomide.

Authors:  S Fabro; R L Smith; R T Williams
Journal:  Nature       Date:  1967-07-15       Impact factor: 49.962

Review 6.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

7.  Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide.

Authors:  T Eriksson; S Björkman; B Roth; A Fyge; P Höglund
Journal:  Chirality       Date:  1995       Impact factor: 2.437

8.  Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  G Reyes-Terán; J G Sierra-Madero; V Martínez del Cerro; H Arroyo-Figueroa; A Pasquetti; J J Calva; G M Ruiz-Palacios
Journal:  AIDS       Date:  1996-11       Impact factor: 4.177

9.  Thalidomide for the treatment of chronic graft-versus-host disease.

Authors:  G B Vogelsang; E R Farmer; A D Hess; V Altamonte; W E Beschorner; D A Jabs; R L Corio; L S Levin; O M Colvin; J R Wingard
Journal:  N Engl J Med       Date:  1992-04-16       Impact factor: 91.245

10.  [Stereoselective differences of central nervous system-depressive action of a homologous series of 3-alkyl-thalidomide analysis].

Authors:  H P Büch; G Omlor; J Knabe
Journal:  Arzneimittelforschung       Date:  1990-01
View more
  9 in total

1.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

2.  Transport of thalidomide by the human intestinal caco-2 monolayers.

Authors:  Shufeng Zhou; Yan Li; Phillip Kestell; Peter Schafer; Eli Chan; James W Paxton
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

Review 3.  Thalidomide in cancer treatment: a potential role in the elderly?

Authors:  Shufeng Zhou; Philip Kestell; Malcolm D Tingle; James W Paxton
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

4.  Chiral Recognition of Hydantoin Derivatives Enabled by Tetraaza Macrocyclic Chiral Solvating Agents Using 1H NMR Spectroscopy.

Authors:  Jie Wen; Lei Feng; Hongmei Zhao; Li Zheng; Pericles Stavropoulos; Lin Ai; Jiaxin Zhang
Journal:  J Org Chem       Date:  2022-06-08       Impact factor: 4.198

Review 5.  Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

Authors:  Tristan M Sissung; Silja Thordardottir; Erin R Gardner; William D Figg
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

Review 6.  Thalidomide and its derivatives: emerging from the wilderness.

Authors:  J N Gordon; P M Goggin
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

7.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10

Review 8.  Significance and challenges of stereoselectivity assessing methods in drug metabolism.

Authors:  Zhuowei Shen; Chuang Lv; Su Zeng
Journal:  J Pharm Anal       Date:  2015-12-21

Review 9.  Clinical pharmacokinetics of thalidomide.

Authors:  Steve K Teo; Wayne A Colburn; William G Tracewell; Karin A Kook; David I Stirling; Markian S Jaworsky; Michael A Scheffler; Steve D Thomas; Oscar L Laskin
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 5.577

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.